UnitedHealth Group reported strong third-quarter results and raised its 2023 earnings outlook to $24.85-$25 per share, reflecting well-balanced growth across its businesses. The company's expansion in value-based care, robust performance in its OptumRx pharmacy services, and positive expectations for Medicare Advantage enrollment indicate sustained momentum. This optimistic guidance and demonstrated adaptability suggest a positive short-term impact on the stock price.

[1]